Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.

Transplantation proceedings - 1 Nov 2009

Tarasewicz A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B

Abstract excerpt

Herein we have reported the use of rapamycin in immunosuppressive treatment after renal transplantation as a therapy of choice in a patient with diagnosis of tuberous sclerosis complex (TSC). TSC is a genetic disorder, caused by mutations of TSC1 or TSC2 genes. Products of these genes, hamartin a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunosuppressive Agents
Share to Kidney Transplantation
Share to Methylprednisolone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Sirolimus

Share to Tacrolimus

Share to Tuberous Sclerosis

Share to Tuberous Sclerosis Complex 1 Protein

Share to Tuberous Sclerosis Complex 2 Protein

Source

Identifiers

PMID: 19917366
DOI: 10.1016/j.transproceed.2009.06.227

Genes

TSC1
TSC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19917366-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.PMID 19917366Read ↗

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosisSemantic proximity Read ↗

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis ComplexSemantic proximity Read ↗

Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.Semantic proximity Read ↗

Perfect match: mTOR inhibitors and tuberous sclerosis complexSemantic proximity Read ↗

Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.Semantic proximity Read ↗

Renal Manifestations of Tuberous Sclerosis ComplexSemantic proximity Read ↗

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disordersSemantic proximity Read ↗

Renal Manifestations of Tuberous Sclerosis ComplexSemantic proximity Read ↗

Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimusSemantic proximity Read ↗

Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutationSemantic proximity Read ↗

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complexSemantic proximity Read ↗

mTOR Inhibitors in Tuberous Sclerosis ComplexSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.